With respect to rare diseases, again, this is another element and another priority of the national pharmaceutical strategy. As I mentioned, Saskatchewan leads the common formulary. Alberta is leading work on how we can address expensive drugs for rare diseases. So work continues on that.
The deputies just met these last several days in Montreal, and this was an issue that came up. A friend of mine and Bob and I were talking earlier about the need to expedite our review processes on that.